How Activity of Inflammatory Bowel Disease Influences Bone Loss

被引:8
|
作者
Orlic, Zeljka Crncevic [1 ]
Turk, Tamara [1 ]
Sincic, Brankica Mijandrusic [2 ]
Stimac, Davor [2 ]
Cvijanovic, Olga [3 ]
Maric, Ivana [3 ]
Tomas, Maja Ilic [4 ]
Jurisic-Erzen, Dubravka [1 ]
Licul, Vanja [2 ]
Bobinac, Dragica [3 ]
机构
[1] Clin Hosp Ctr Rijeka, Dept Endocrinol Diabet & Metab Dis, Rijeka, Croatia
[2] Clin Hosp Ctr Rijeka, Dept Gastroenterol, Rijeka, Croatia
[3] Univ Rijeka, Sch Med, Dept Anat, Rijeka, Croatia
[4] Univ Rijeka, Dept Physiol & Immunol, Rijeka, Croatia
关键词
Corticosteroids; duration and activity of disease; IBD; osteoporosis; MINERAL DENSITY; CROHNS-DISEASE; ULCERATIVE-COLITIS; INDUCED OSTEOPOROSIS; METABOLISM; OSTEOPENIA; FRACTURE;
D O I
10.1016/j.jocd.2009.12.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bone loss is a common problem for individuals with inflammatory bowel disease (IBD). The aim of our study was to assess bone mineral density (BMD) in patients with IBD and to investigate the role of corticosteroid (CS) use and duration and activity of disease on BMD. Ninety-two patients (56 men and 36 women) with IBD, of whom 32 had ulcerative colitis (UC) and 60 had Crohn's disease (CD), underwent clinical assessment. Lumbar and femoral neck BMDs were measured by dual-energy X-ray absorptiometry. Osteopenia was observed in 14 patients (43%) with UC and in 24 patients (40%) with CD (p = 0.187). Four patients (12%) with UC and 7 patients (11%) with CD had osteoporosis (p = 0.308). Femoral BMD decreased in patients with long duration of CS use and correlated inversely with disease activity. Multiple regression analysis of BMD showed that statistically significant risk factors were duration of active disease and body mass index as well. Based on our results, it is necessary to take into account the risk of decreased BMD in patients with IBD. It is most important to achieve disease remission as soon as possible in addition to nutritional support.
引用
收藏
页码:36 / 42
页数:7
相关论文
共 50 条
  • [1] Association of vitamin K deficiency with bone metabolism and clinical disease activity in inflammatory bowel disease
    Nakajima, Sachiko
    Iijima, Hideki
    Egawa, Satoshi
    Shinzaki, Shinichiro
    Kondo, Jumpei
    Inoue, Takahiro
    Hayashi, Yoshito
    Ying, Jin
    Mukai, Akira
    Akasaka, Tomofumi
    Nishida, Tsutomu
    Kanto, Tatsuya
    Tsujii, Masahiko
    Hayashi, Norio
    NUTRITION, 2011, 27 (10) : 1023 - 1028
  • [2] Bone health in inflammatory bowel disease
    Wei, Hao
    Zhao, Yihan
    Xiang, Lisha
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2023, : 921 - 935
  • [3] Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease
    Kriel, M. H.
    Tobias, J. H.
    Creed, T. J.
    Lockett, M.
    Linehan, J.
    Bell, A.
    Przemioslo, R.
    Smithson, J. E.
    Brooklyn, T. N.
    Fraser, W. D.
    Probert, C. S. J.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 (03) : 507 - 513
  • [4] Bone density and bone metabolism in patients with inflammatory bowel disease
    Shirazi, Kourosh M.
    Somi, Mohammad H.
    Rezaeifar, Parisa
    Fattahi, Ibrahim
    Khoshbaten, Manuchehr
    Ahmadzadeh, Masoumeh
    SAUDI JOURNAL OF GASTROENTEROLOGY, 2012, 18 (04) : 241 - 247
  • [5] Bone Health in Children With Inflammatory Bowel Disease: Adjusting for Bone Age
    Hill, Rebecca J.
    Brookes, Denise S. K.
    Lewindon, Peter J.
    Withers, Geoffrey D.
    Ee, Looi C.
    Connor, Frances L.
    Cleghorn, Geoffrey J.
    Davies, Peter S. W.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2009, 48 (05) : 538 - 543
  • [6] Signaling pathways associated with bone loss in inflammatory bowel disease
    Palatianou, Maria E.
    Karamanolis, George
    Tsentidis, Charalambos
    Gourgiotis, Dimitrios
    Papaconstantinou, Ioannis
    Vezakis, Antonios
    Tzouvala, Maria
    ANNALS OF GASTROENTEROLOGY, 2023, 36 (02): : 132 - 140
  • [7] Frequency of Low Bone Mineral Density in Saudi Patients with Inflammatory Bowel Disease
    Ismail, Mona H.
    Al-Elq, Abdulmohsen H.
    Al-Jarodi, Mandi E.
    Azzam, Nahla A.
    Aljebreen, Abdulrahman M.
    Al-Momen, Sami A.
    Bseiso, Bahaa F.
    Al-Mulhim, Fatma A.
    Alquorain, Abdulaziz
    SAUDI JOURNAL OF GASTROENTEROLOGY, 2012, 18 (03) : 201 - 207
  • [8] The effects of dihydroartemisinin on inflammatory bowel disease-related bone loss in a rat model
    Ge, Xingtao
    Chen, Zhijian
    Xu, Zhenjie
    Lv, Fang
    Zhang, Kewei
    Yang, Yu
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2018, 243 (08) : 715 - 724
  • [9] Risk Factors for Worsening of Bone Loss in Patients Newly Diagnosed with Inflammatory Bowel Disease
    Yin, Yi
    Lu, Xiaofeng
    Li, Zhun
    Liu, Song
    Shao, Lihua
    Cao, Lei
    Liu, Rui-Qing
    Huang, Liang-Yu
    Zhu, Zhen-Xing
    Guo, Zhen
    Li, Yi
    Zhu, Wei-Ming
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2022, 2022
  • [10] Clinical relevance of changes in bone metabolism in inflammatory bowel disease
    Miheller, Pal
    Lorinczy, Katalin
    Lakatos, Peter Laszlo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (44) : 5536 - 5542